News

Events
2017 EBD Biotech Showcase
RepliCel presented and conducted one-on-one partnering meetings.
Press Release
RepliCel CEO Provides 2017 Forecast
After a year of restructuring, RepliCel poised for multiple clinical trial data announcements and completion...
Press Release
The Jake Brown Show
Episode 10: SNY’s Taylor Rooks, Stylist Megan Wilson, Replicel’s Lee Buckler Released Dec 07, 2016...
As Seen In
Total Tutor with Neil Haley
The Total Tutor Neil Haley will interview Lee Buckler of Replicel. Click here to view:...
Press Release
RepliCel Life Sciences Announces Closing of Private Placement
Completed Financing Positions RepliCel Through Upcoming Milestones VANCOUVER, BC – October 31, 2016 – RepliCel...
Press Release
RepliCel Life Sciences Amends Terms of Private Placement
 NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...
Press Release
RepliCel Announces Debt Settlement
VANCOUVER, BC – September 27, 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCD) (TSXV: RP)...
Press Release
RepliCel Provides Update on Shiseido License and Co-Development for RCH-01
VANCOUVER, BC – September 26 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCD) (TSXV: RP)...
Press Release
RepliCel Life Sciences Announces Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...
Press Release
Replicel Life Sciences Share Consolidation Approved
Capital Structure Restructuring Expected to Lead to Financing and Milestones VANCOUVER, BC – August 9,...
Press Release
Replicel Life Sciences Continues Restructuring with Share Structure Consolidation
VANCOUVER, BC – July 22, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)...
Press Release
RepliCel’s Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan
VANCOUVER, BC – July 21, 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP)...
Press Release
Replicel Life Sciences Extends Warrant Expiry Dates and Amends Warrant Exercise Price
VANCOUVER, BC – April 29, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)...
Press Release
RepliCel Life Sciences conducts formal consultation review with Japan’s PMDA and receives unprecedented review fee reduction
Japan’s Pharmaceuticals and Medical Devices Agency reviews RepliCel’s pre-clinical, quality, and manufacturing data for its...
Press Release
RepliCel Life Sciences Finishes Enrolment for its Tendon Repair and Skin Rejuvenation Clinical Trials
Results from both trials will support commercialization initiatives, partner discussions and continued clinical developmentVANCOUVER, BC...
Press Release
Replicel Life Sciences Applies to Amend Warrant Exercise Price and Extend Warrant Expiry Dates
VANCOUVER, BC – April 8, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)...
Press Release
RepliCel Life Sciences Announces Restructuring, Cost Reductions and Closing of Private Placement
VANCOUVER, BC – April 6, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)...
As Seen In
Shiseido to trial baldness ‘cure’ for planned commercial launch in 2018
Find full article here online, at The Asahi Shimbun.
As Seen In
Embrace Low-Cap Biotech for High Gains: Eden Rahim of Next Edge Capital
Source: George S. Mack of The Life Sciences Report (3/2/16) View the full article as...
Press Release
Investor Hub News Releases Financials Analyst Coverage Events SEDAR Filings EDGAR Filings Presentations & Fact Sheets Corporate Governance Info Request Videos RepliCel Life Sciences Inc. Announces Closing of Warrant Incentive Program
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED...

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.